Phase II trial of neoadjuvant bevacizumab (BEV), capecitabine (CAP), and radiotherapy (XRT) for locally advanced rectal cancer

Christopher H. Crane, Cathy Eng, Barry W. Feig, Priyanka Das, J. M. Skibber, George J. Chang, Robert A. Wolff, S. Krishnan, Dipen M. Maru, L. M. Ellis,

Journal of Clinical Oncology · 2008 · 16 citations · 0 references

Concepts

Abstract

4091 Background: Anti-VEGF therapy may lead to enhanced tumor response or increased toxicity in patients treated with neoadjuvant chemoradiation. We designed a phase II trial to assess the efficacy and safety of BEV with neoadjuvant CAP-based chemoradiation in locally advanced rectal cancer. Methods: Between April 2004 and December 2007, 25 patients EUS/CT staged T3/N1 (19) or T3 N0 (6) rectal cancer were treated with neoadjuvant XRT (50.4 Gy in 28 fractions over 5.5 weeks using a posterior 3-field technique), BEV intraveneously every 2 weeks (5 mg/kg for 3 doses), and CAP 900 mg/m2 PO twice daily only on days of radiation (Monday through Friday). Surgical resection followed a median of 7.3 weeks (range 5.9–11) after the completion of chemoradiation. Results: Eight of 25 patients (32%) had pathologic complete response (pCR), and 6/25 (24%) had <10% viable tumor cells in the specimen. Overall sphincter preservation (SP) rate was 18/25 (72%). Procedures included abdominoperineal resection (APR, 6), proctectomy with coloanal anastamosis (8), and low anterior resection (10). All patients with SP underwent initial diverting iliostomy. With a median FUof 22.1 months (range 3.3–30.5), all patients are alive, there has been one pelvic recurrence (2 yr actuarial rate 7%) and 3 distant recurrences. No patient had grade 3 HFS or gastrointestinal (GI) toxicity; CAP was held for greater than 2 days in 4 patients and the dose was reduced by 25% in 3 patients for grade 2 HFS, fatigue or GI toxicity. There was no significant hematologic toxicity, ATEs or DVTs. There were three wound complications that required surgical intervention (one coloanal anastamostic dehiscence requiring completion APR, and two perineal wound dehiscences after initial APR). Five minor complications that resolved without operative intervention (2 delayed perineal wound healing, 2 anastomotic leaks and a superficial wound infection). Conclusions: The addition of BEV to neoadjuvant chemoradiation resulted in encouraging pCR and local tumor control rates without an increase in acute toxicity. The risk of perineal wound complication due to concurrent BEV and the timing of surgery requires further study. Supported by Genentech, Inc. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Genentech Genentech, Roche Genentech